Expression pattern of synaptic vesicle protein 2 (SV 2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: Synaptic vesicle proteins 2 (SV 2) are neuronal vesicles membrane glycoproteins that appear as important targets in the treatment of partial and generalized epilepsies. Therefore, we analysed the expression of SV 2 isoforms in the hippocampus of patients with temporal lobe epilepsy (TLE). Methods: SV 2 A, SV 2 B and SV 2 C immunostaining and Q uanti G ene branched DNA assay were performed on biopsies from 31 consecutive TLE patients with mesial temporal sclerosis (MTS) and compared with 10 autopsy controls. SV 2 expression was further compared with T imm's staining, and synaptophysin, Z inc transporter 3 (ZnT 3), dynorphin, vesicular glutamate transporter 1 (VGLUT 1) and vesicular GABA transporter (VGAT) expression. Results: In TLE patients, SV 2 A and SV 2 B expression was decreased in areas of synaptic loss. SV 2 C, which is weakly expressed or absent in the hippocampus of controls, was overexpressed in 10/11 cases with classical MTS 1 A and mossy fibre sprouting but not in cases with other types of MTS. SV 2 C staining was located in the inner molecular layer of the dentate gyrus and colocalized with dynorphin, ZnT 3 and VGLUT 1, suggesting selective expression in presynaptic glutamatergic Zn2+‐rich terminals of abnormal sprouting fibres. SV 2 expression patterns correlated with histological subtypes of MTS, but not with clinical features or therapeutic regimens in this patient cohort. Conclusion: In classical MTS 1 A, the expression of SV 2 isoforms is altered with a marked decrease of SV 2 A and SV 2 B paralleling synaptic loss and a selective increase of SV 2 C in sprouting mossy fibres. These findings suggest a different physiology of sprouting synapses and the possibility to target them with SV 2 C‐specific strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy
van Vliet, E. A., da Costa Araujo, S., Redeker, S., van Schaik, R., Aronica, E., & Gorter, J. A. (2007) · Brain · doi:10.1093/brain/awl318 · Cited by 775
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415
Gorter, J. A., van Vliet, E. A., Aronica, E., Breit, T., Rauwerda, H., Lopes da Silva, F. H., & Wadman, W. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-06.2006 · Cited by 316
SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis
Chang, W.-P., & Südhof, T. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4521-08.2009 · Cited by 176
Gillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148
Cited by
Imaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575
Review: Hippocampal sclerosis in epilepsy: a neuropathology review
Thom, M. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12150 · Cited by 563
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
“[70] studied the expression pattern of all three isoforms of SV2 in the hippocampus of patients with TLE and hippocampal sclerosis.”
BackgroundSelf-citationPET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
Koole, M., van Aalst, J., Devrome, M., Mertens, N., Serdons, K., Lacroix, B., Mercier, J., Sciberras, D., Maguire, P., & Van Laere, K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4119-8 · Cited by 118
Puzzling Out Synaptic Vesicle 2 Family Members Functions
Bartholome, O., Van den Ackerveken, P., Sánchez Gil, J., de la Brassinne Bonardeaux, O., Leprince, P., Franzen, R., & Rogister, B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00148 · Cited by 107
Self-citationEvaluation of18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85
“Reduced expression of SV2A and SV2B in areas of synaptic loss in temporal lobe epilepsy and a selective increase in SV2C expression in sprouting mossy fibers in mesial temporal sclerosis have been reported (4), further indicating a role for SV2 in epilepsy and related neurodegeneration.”
BackgroundFinnema, S. J., Toyonaga, T., Detyniecki, K., Chen, M., Dias, M., Wang, Q., Lin, S., Naganawa, M., Gallezot, J., Lu, Y., et al. (2020) · Epilepsia · doi:10.1111/epi.16653 · Cited by 78
Tokudome, K., Okumura, T., Shimizu, S., Mashimo, T., Takizawa, A., Serikawa, T., Terada, R., Ishihara, S., Kunisawa, N., Sasa, M., et al. (2016) · Scientific Reports · doi:10.1038/srep27420 · Cited by 75
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77
[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A
Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.004 · Cited by 71
“Studies in brain tissue from patients that died from status epilepticus or from pharmacoresistant temporal lobe epilepsy patients showed that they had a reduced SV2A expression in hippocampus [8] compared to levels measured in the brain from nonepileptic patients.”
Li, S., Naganawa, M., Pracitto, R., Najafzadeh, S., Holden, D., Henry, S., Matuskey, D., Emery, P. R., Cai, Z., Ropchan, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05149-3 · Cited by 61
“Synaptopathy, change and/or abnormality in the function and structure of synapses, has been frequently observed in patients with neurodegenerative disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3], and epilepsy [4, 5], as well as psychiatric diseases such as depression [6], schizophreni…”
BackgroundKinetics and 28-day test–retest repeatability and reproducibility of [ 11 C]UCB-J PET brain imaging
Tuncel, H., Boellaard, R., Coomans, E. M., de Vries, E. F., Glaudemans, A. W., Feltes, P. K., García, D. V., Verfaillie, S. C., Wolters, E. E., Sweeney, S. P., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20964248 · Cited by 45
Prada Jardim, A., Liu, J., Baber, J., Michalak, Z., Reeves, C., Ellis, M., Novy, J., de Tisi, J., McEvoy, A., Miserocchi, A., et al. (2018) · Brain Pathology · doi:10.1111/bpa.12514 · Cited by 40
Pharmacokinetic Characterization of [18F]UCB-H PET Radiopharmaceutical in the Rat Brain
Becker, G., Warnier, C., Serrano, M. E., Bahri, M. A., Mercier, J., Lemaire, C., Salmon, E., Luxen, A., & Plenevaux, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00235 · Cited by 31
Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C
Peng, C., Zhu, G., Liu, X., & Li, H. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0230-x · Cited by 16
Metadata
- Authors
- Crèvecœur, J., Kaminski, R. M., Rogister, B., Foerch, P., Vandenplas, C., Neveux, M., Mazzuferi, M., Kroonen, J., Poulet, C., Martin, D., Sadzot, B., Rikir, E., Klitgaard, H., Moonen, G., & Deprez, M.
- Venue
- Neuropathology and Applied Neurobiology
- Publisher
- Wiley
- Published
- 2014-01-21
- Volume
- 40
- Issue
- 2
- Pages
- 191-204
- ISSN
- 0305-1846 (ISSN-L)
- 1365-2990
- OpenAlex
- W2130673921
- Cited by
- 68
- References
- 6
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.